WORLD NEWS
WHO recommends doxycycline within 72 hours for some bacterial STI prevention
The World Health Organization has issued its first global recommendation on doxycycline post-exposure prophylaxis, or DoxyPEP, to reduce bacterial sexually transmitted infections.
Clinicians may conditionally offer one 200 mg dose, ideally within 24 hours and no later than 72 hours after condomless sex, to MSM and transgender women at higher risk of recent or recurrent infection.
The prevention effect in trials
WHO’s integrated randomized-trial evidence found reductions of 80% for syphilis, 85% for chlamydia and 48% for gonorrhoea. In a US trial of 501 people, quarterly bacterial STI incidence fell by roughly two thirds. Gonorrhoea protection varied with local tetracycline resistance.
Who the recommendation covers
WHO prioritizes MSM and transgender women with an STI in the previous 12 months or exposure in high-incidence networks. Prescribing must sit within sexual-health services that include regular testing, HIV prevention or care, vaccination, condoms and counselling.
Where evidence is missing
A randomized trial in 449 cisgender women in Kenya did not show a significant reduction. Adherence was low and gonorrhoea isolates had high tetracycline resistance. WHO says evidence is insufficient to extend the recommendation to cisgender women, adolescents or other groups and does not recommend daily DoxyPrEP.
Why it should not be taken without care
Doxycycline is a prescription antibiotic and can cause nausea, oesophageal irritation and sun sensitivity. The larger concern is antimicrobial resistance. Long-term effects on the gut microbiome and resistance in other bacteria remain uncertain.
What a person should check
This is not an instruction to obtain and take antibiotics independently. Eligibility, testing, medicine interactions and local resistance monitoring should be reviewed with a clinician or an official sexual-health programme.
Official Primary Sources
WHO: full DoxyPEP guideline, evidence tables and monitoring conditions
WHO: first global DoxyPEP recommendation announcement
NEJM: randomized DoxyPEP trial in 501 MSM and transgender women